Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.
In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following list of names for the drugs described are "under consideration" by the USAN Council:
|allopregnanolone||treatment of refractory status epilepticus (RSE)|
|axileugencel-T||antineoplastic; cellular therapy|
|citarinostat||treatment of hematologic malignacies|
|dezapelisib||treatment of hematologic malignancies|
|fenevetmab||treatment of osteoarthritis pain in cats|
|mardecamp||treatment of Huntington’s disease|
|mardecamprin||treatment of Huntington’s disease|
|midmafetamine||adjunct to psychotherapy in the treatment of PTSD|
|rebaxamase||preventing side effects associated with IV administration of β-lactam antibiotics|
|baliforsen||treatment of myotonic dystrophy type I|
|dasifimod||treatment of autoimmune and inflammatory diseases|
|embifungin||treatment of candidemia and invasive candidiasis in adults; antifungal|
|etrasimod||treatment of autoimmune and inflammatory diseases|
|flamigolix||treatment of endometriosis|
|fluriopane I 123||radiolabeled diagnostic agent for Parkinson’s disease|